miR-429 enhanced the sensitivity of gastric cancer cells to cisplatin by decreasing the expression of SOX2 and inhibiting PI3K/Akt/mammalian target of rapamycin (mTOR) signaling [111]. Here, MTOR is linked to gastric cancer.